Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is set to present new preclinical data on its TNX-801 mpox vaccine candidate at the upcoming Vaccine Congress 2025 in Vienna. The presentation, scheduled for July 10, will be delivered by Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development at Tonix. TNX-801, a recombinant horsepox virus live vaccine, has demonstrated protective efficacy against mpox and other orthopoxviruses in animal models following a single dose. This development is significant as it underscores the vaccine's potential to offer durable immune responses and its adaptability to target emerging viral threats.
The data to be presented will cover safety, immunogenicity, and efficacy findings, alongside plans for initiating clinical trials. This announcement is crucial for the public health sector, as it represents a proactive step towards addressing the mpox virus, which has been a concern for global health security. The ability of TNX-801 to potentially provide protection with a single dose could simplify vaccination campaigns and enhance global preparedness against mpox and related viruses.
Tonix Pharmaceuticals' commitment to advancing TNX-801 is part of its broader mission to modernize solutions for public health challenges. The company's state-of-the-art facilities and its focus on developing innovative vaccines and therapeutics position it as a key player in the biopharmaceutical industry's response to infectious diseases. The presentation at Vaccine Congress 2025 will offer valuable insights into the progress of TNX-801 and its implications for future public health strategies.
